This month's Broker Brief breaks down: - Why up to 65% of GLP-1 users discontinue within a year, and why that turns coverage into a sunk cost for employers - What oral GLP-1s like Lilly's Foundayo mean for demand, when most plans still have eligibility rules written for injectables only - How fast a PBM formulary decision can move, using this year's Zepbound to Wegovy switch and back as the case in point - Why 38% of employers already tie GLP-1 coverage to participation in a lifestyle or behavioral program If you're advising employers on GLP-1 coverage, this is where the conversation is heading
The other side: A CVS Caremark spokesperson told Bloomberg Law the lawsuit is "without merit." "Well defend ourselves vigorously against those claims," the spokesperson said
Once I accomplished that, they would take fat from my inner and outer thighs, flanks, and arms
Las grasas juegan diferentes papeles en nuestro organismo, entre los que destacan su funcin estructural, de reserva y aporte energtico, protectora y de aislante trmico, as como su funcin reguladora al actuar algunos lpidos como hormonas y vitaminas